Pfizer surpasses profit expectations in Q2, driven by strong Eliquis sales, reporting 77 cents per share versus 68 cents expected.
Pfizer beat Wall Street estimates
for second-quarter profit on Tuesday, driven by strong demand
for its blood thinner, Eliquis.On an adjusted basis, the company reported a profit of 77
cents per share, compared with analysts' estimates of 68 cents
per share, according to data compiled by LSEG.
Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts
Drugmaker Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts
What's Going on With Pfizer Stock Tuesday? - Pfizer (NYSE:PFE)
Pfizer Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analy
Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products
Pfizer raises sales guidance on high demand for older drugs
Pfizer Raises Sales Guidance on High Demand for Older Drugs
Eli Lilly Stock: How To Earn $500 A Month Ahead Of Q2 Earnings - Eli Lilly (NYSE:LLY)
Dow Jumps Over 700 Points; Pfizer Posts Upbeat Q2 Earnings - Pfizer (NYSE:PFE), SU Group Holdings (NASDAQ
Pfizer reverte lucro e tem prejuízo de US$ 248 milhões no 2º trimestre
